The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Looking Back on Rheumatology in 2015, Leaping Forward to the Year Ahead

Looking Back on Rheumatology in 2015, Leaping Forward to the Year Ahead

December 16, 2015 • By Simon M. Helfgott, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Contracts with large insurers provide enormous clout to PBMs when negotiating with drug manufacturers and pharmacies. This became evident this past year when certain PBMs battled pharmaceutical firms over coverage for the newer, more costly drugs used to treat hepatitis C and over the indications for the use of the PCSK9 lipid-lowering biologics.8

You Might Also Like
  • Rheumatology Coding Corner Year-End Quiz Answers
  • The ACR: Looking Ahead to 2015 and Beyond
  • Rheumatology Coding Corner Answers: 2017 End-of-Year Quiz
Explore This Issue
December 2015
Also By This Author
  • Gene Manipulation Has Potential to Alter Genomes, Impact Society

Our most stressful interactions with PBMs revolve around their demands to complete prior authorizations (PAs) for an ever-expanding list of drugs. Sometimes, the reasoning for a PA is obvious; the drugs we chose may be costly or the PBM has signed a contract with a specific manufacturer that offers it better rebates when we choose others. However, in a growing number of instances, the PA is required for even the cheapest generics. Examples: prednisone, alendronate, omeprazole and yes, folic acid, too. From a cost perspective, this makes no sense, and the time you waste explaining your medical judgment is of no concern to the PBM. This activity is such a far cry from why you chose to become a doctor. To paraphrase Bob Dylan, 20 years of schooling, and they put you on the day shift!

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On an optimistic note, state legislatures have been pushing for greater transparency and disclosure provisions to better regulate PBMs. In addition, there has been pressure to force fiduciary duty onto PBMs that would require them to act in the best interest of insurers and insurance plans, similar to how financial advisors have a legal obligation to act in the best interest of their clients.7 Can these rules slow the PBM juggernaut? Stay tuned in 2016.

Lessons from MOC

In 2015, we witnessed the abrupt turnaround by the American Board of Internal Medicine (ABIM) regarding the imposition and now partial retraction of some of the more onerous maintenance of certification (MOC) requirements. Following an unprecedented campaign in which doctors and organizations, including the ACR, took a vocal stand and opposed its implementation, the ABIM issued a mea culpa.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Earlier, the ACR declared that “It is incumbent upon the ABIM … to engage a respected independent [the College’s underline] party to assess the impact of the MOC program and make the findings publicly available.”9

We took a stand, we organized, and we made our views known. What does this teach us? We can no longer sit by idly, gazing at our computer screens, expecting the insurers, the PBMs and the other major players in healthcare to ease their ceaseless demands. How can we, as a small specialty, have any impact on the future agenda of healthcare? There is only one way, which is for us to organize and start supporting our very own political action committee, RheumPAC.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Legislation & Advocacy, Practice Management, Professional Topics, Rheuminations Tagged With: Legislation & Advocacy, Practice Management, Professional Topics, RheuminationsIssue: December 2015

You Might Also Like:
  • Rheumatology Coding Corner Year-End Quiz Answers
  • The ACR: Looking Ahead to 2015 and Beyond
  • Rheumatology Coding Corner Answers: 2017 End-of-Year Quiz
  • Congress Can Begin Work to Advance Rheumatology Before New Year

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.